EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study
Oct 2026· HemaSphere· Vol 10· 0 citations· 22 references
Medicine
TL;DR
Follicular lymphoma is the most common indolent lymphoma and next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D, CREBBP, and EZH2 ).
Abstract
Follicular lymphoma (FL) is the most common indolent lymphoma, 1,2 a biologically and clinically heterogeneous entity with a diverse genetic landscape and characterized by slowly progressive but relapsing clinical course. 3 The t(14;18) translocation driving BCL ‐ 2 overexpression is present in 85% – 90% of patients 4 although additional genetic events are required for lymphomagenesis. Next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D , CREBBP , and EZH2 ). 5,6 EZH2 encodes the catalytic subunit of the Polycomb repressor complex 2 and mediates H3K27 methylation. Missense mutations in EZH2
CD20, encoded by MS4A1 , is one of the earliest and most extensively used immunotherapeutic targets in B ‐ cell malignancies and the mechanisms underlying resistance remain poorly understood.
A. Guijosa, N. Tsakmaklis, S. Dhe-Paganon et al.· HemaSphere· 0 citations
Long-term data is provided across essential thrombocythaemia, post-ET myelofibrosis and primary MF, highlighting the prognostic relevance of additional somatic mutations in CALR-mutated myeloproliferative neoplasms.
G. G. Loscocco· British Journal of Haematolo...· 0 citations
Older adults (aged ≥ 55 years) with Philadelphia chromosome-neg-ative B-cell acute lymphoblastic leukemia (B-ALL) frequently present with adverse cytogenetic features, poor treatment tolerance, and inferior long-term outcomes [1, 2]. While intensive chemotherapy remains the standard first-line approach, its clinical ef...
Kai-Hang Shi, Jing Zhou, Gao-Xiang Wang· Archives of Medical Science· 0 citations
Background: Selpercatinib is approved for RET-mutated medullary thyroid carcinoma (MTC); its activity in tumors without detectable RET alterations is uncertain. Patient Findings: A 50-year-old woman developed rapidly progressive MTC (Ki-67 = 30%) with extensive liver and bone metastases. Because of severe symptomatic p...
A. Alzahrani, Allianah D. Benito, B. Alghamdi et al.· Thyroid· 0 citations
Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL
L. Wang, K. Zhou, Fei Li et al.· HemaSphere· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.